Interview 21 Jun 2017 Video: Can Synbio Cure Malaria? – Fireside Chat with Oxitec’s CEO Hadyn Parry In our fireside chat with Hadyn Parry, Clara had the chance to hear all about Oxitec’s exciting technology that could save us from Dengue and Zika. Oxitec’s GM mosquitoes have the potential to halt epidemics of mosquito-borne diseases such as Zika or Dengue, which according to Hadyn are actually causing more problems every year. As Hadyn explained, “we’re […] June 21, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2017 British Biotech Tops up its Cancer Pipeline with New TCR Therapy Cell Medica just acquired Catapult Therapy TCR, set up by UK’s CGT Catapult, gaining the rights to its TCR therapy candidate to treat solid tumors. Cell Medica says it’s all set to leverage its Dominant T cell receptor (TCR) platform technology, which the company licensed from University College London (UCL) last year, to enhance existing T cell […] June 21, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 21 Jun 2017 Swedish IPO raises €51M for Biomaterials to Repair Bone Bonesupport has gone public in the Swedish stock market to push its pipeline and increase sales of biomaterials to regenerate bone tissue. Bonesupport is a company based in Lund, Sweden, that develops biomaterials to improve and speed up the repair of bones. The firm IPO’d today on the Nasdaq Stockholm, raising an impressive €51M with the participation […] June 21, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Infographics 21 Jun 2017 Check Out these 42 European SynBio Startups Reimagining the Industry Synthetic biology, or synbio for short, is rapidly infiltrating multiple fields. From bioplastics to food technology and healthcare, these are the startups in Europe that are expanding the frontiers of what synbio can do to improve our lives in many different ways. In the not-so-distant future, synthetic biology could bring us anything from spider silk […] June 21, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2017 Swedish Biotech publishes Long-Term Data on a Dendritic Cell Therapy for Cancer Immunicum has reported new data on long-term follow-up of patients treated with ilixadencel, a unique dendritic cell therapy against cancer. Immunicum is a Swedish biotech developing a cell-based therapy against cancer. The company has just published in the Journal for Immunotherapy for Cancer detailed results from a Phase I/II trial evaluating its lead candidate ilixadencel. The cell […] June 20, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2017 Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials Bayer’s and Regeneron’s blockbuster Eylea could be facing serious competition, as Novartis boasts with positive Phase III results for AMD. Novartis has been struggling on the age-related macular degeneration (AMD) market since its Roche-partnered VEGF-A inhibitor Lucentis was outperformed by Eylea from Bayer and Regeneron, which required a less-frequent dosing schedule and was placed at a lower […] June 20, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 20 Jun 2017 Belgian Llama Antibody Developer gets Second Preclinical Milestone from Danish Pharma argenx’s 2015 deal with Leo Pharma for anti-inflammatory antibodies continues to pay off, though it hasn’t been disclosed by how much exactly. Two years ago, Ghent-based argenx and Danish Leo Pharma teamed up to develop antibodies to counter inflammatory diseases in a deal totalling €105M. argenx just received its second preclinical milestone for granting Leo access to […] June 20, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 20 Jun 2017 “We’re at a second revolution in cancer therapy” – Experts discuss the Future of Oncology at Refresh A panel of experts in immuno-oncology discussed the challenges and opportunities to develop therapies that can effectively fight cancer. “I think right now we’re at a second revolution in cancer therapy, which surprisingly is not necessarily driven by technology but perspective, and how we look at cancer,” said Masoud Tavazoie, CEO of Rgenix. His company, based in New York, […] June 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 19 Jun 2017 Video: “Biotech is still in its Infancy” – Keynote by Boston’s Prominent Biotech VC We were very excited that David Berry, General Partner at Flagship Pioneering, opened Refresh earlier this month with a keynote on how far biotech has come. David has extensive experience in the biotech field and holds over 200 patents and patent applications. He has co-founded and helped build more than 20 companies during his time at […] June 19, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jun 2017 This Company Uses the Human Microbiome to Discover New Disease Mechanisms A whole new avenue to human health and disease could soon be accessible, thanks to the human tissue microbiome. Vaiomer has found a way to make it possible! Has anyone else ever been unsettled by the idea that the human body hosts about 10 times more microbes than human cells? Although this might seem an […] June 19, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 19 Jun 2017 Discussing the Virtual Biotech Model with XO1 Co-Founder Trevor Baglin Academic, entrepreneur and now venture partner Trevor Baglin discusses his successful experience working with the unique model of virtual biotech. Trevor Baglin, along with Jim Huntington and David Grainger, is one of the members of the team behind XO1, a virtual biotech founded in 2013 and acquired by Janssen Pharmaceuticals just two years later […] June 19, 2017 - 7 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 16 Jun 2017 Meet the Swedish Biotech that is Set to Cure a Rare Kidney Disease This week we visited the Scandinavian summer and had a look at the Swedish biotech Oxthera, which is developing cell- and enzyme-based therapies to treat hyperoxaluria. Mission: Stockholm-based Oxthera is currently advancing two late-stage clinical products for the treatment of primary and secondary hyperoxaluria, a kidney disease that is caused by the build-up of oxalate in plasma […] June 16, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email